Hepatitis :: China’s SFDA stops blood drug over hepatitis C fears

China has suspended the production and sale of an intravenously injected blood-based drug used to treat immune system deficiencies after users were feared to have contracted hepatitis C.

China’s State Food and Drug Administration, said that the Guangdong Bioyee Pharmaceutical Co. Ltd. had committed “illegal behaviour” in the production of its immunoglobulin drug and that users had tested positive to “Hepatitis C antibodies”.

Investigations by health authorities had found that some of the products lacked proper production and inspection records. The plasma used to make the immunoglobulin drug might have contained either the hepatitis C virus or its antibodies.


Leave a Comment